Security Snapshot

Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) Institutional Ownership

CUSIP: 61225M102

13F Institutional Holders and Ownership History from Q2 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

135

Shares (Excl. Options)

70.78MFull value: 70,778,806 · shares · 30 Sep 2026

Price

$11.93

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+567,034
Value change
-$34,381,178
Number of holders
135
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
85,943,909
SEC-reported price per share
$11.26
Insider filing price
$11.26
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 61225M102.
  • 135 institutions reported positions in Q3 2026.
  • 12 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 192 to 135 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.24BFull value: $2,241,872,344 · USD · 30 Jun 2026
    to
    $844.31MFull value: $844,305,006 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 135 institutions filings for Q3 2026.

Open SEC evidence

Security key

61225M102

13F reference period

Q3 2026

13F holders

135

13D/G owners

12

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
12
Security
GLUE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 10% +47% $155,158,528 +$79,195,063 8,876,346 +104% Baker Bros. Advisors LP 31 Mar 2026
PRICE T ROWE ASSOCIATES INC /MD/ 8.6% -17% $82,838,300 -$16,939,735 7,356,865 -17% T. Rowe Price Associates, Inc. 30 Sep 2026
Vestal Point Capital, LP 8.4% +60% $80,283,800 +$28,487,800 7,130,000 +55% Vestal Point Capital, LP 30 Sep 2026
New Enterprise Associates 17, L.P. 7.9% -18% $109,552,918 -$18,084,463 6,692,298 -14% New Enterprise Associates 17, L.P. 01 Jul 2026
Dimension Capital I, L.P. 8.1% -6.7% $107,152,737 +$13,990,895 6,513,765 +15% Adam Goulburn 31 Mar 2026
BIOTECHNOLOGY VALUE FUND L P 5% -22% $48,154,268 -$9,112,808 4,276,578 -16% BVF PARTNERS L P/IL 30 Sep 2026
BlackRock, Inc. 6.3% $20,045,661 3,840,165 BlackRock, Inc. 31 Dec 2024
TCG Crossover GP II, LLC 4.4% -18% $42,580,050 -$9,465,370 3,781,532 -18% Chen Yu 30 Sep 2026
MONTANOVA CAPITAL, LLC 4.2% -22% $85,401,908 +$4,560,308 3,549,539 +5.6% Montanova Capital, LLC 30 Jun 2026
VANGUARD GROUP INC 4.8% -6% $22,148,142 -$1,240,441 2,988,953 -5.3% The Vanguard Group 30 Sep 2025
Versant Venture Capital VI, L.P. 3.4% -34% $35,080,976 -$17,220,640 2,236,708 -33% Versant Venture Capital VI, L.P. 07 Jan 2026
FMR LLC 2.8% $7,072,953 1,750,731 FMR LLC 30 May 2025
As of 30 Sep 2026, 135 institutional investors reported holding
70.78MFull value: 70,778,806 · shares · 30 Sep 2026
shares of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE). This represents 82% of the company’s total
85.94MFull value: 85,943,909 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
69%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Vestal Point Capital, LP 8.3% 7,130,000 2.2% $85,060,900
NEA Management Company, LLC 7.8% 6,692,298 5.9% $79,839,115
BAKER BROS. ADVISORS LP 5.1% 4,345,736 0.25% $51,844,630
BVF INC/IL 5% 4,276,578 1.7% $51,019,576
TCG Crossover Management, LLC 4.4% 3,781,532 1.3% $45,113,677
STATE STREET CORP 4.3% 3,722,186 0% $44,405,679
VANGUARD CAPITAL MANAGEMENT LLC 4% 3,475,954 0% $41,468,131
Versant Venture Management, LLC 3.7% 3,180,780 35% $37,946,705
SILVERARC CAPITAL MANAGEMENT, LLC 3.6% 3,112,773 4.5% $37,135,382
MONTANOVA CAPITAL, LLC 3.4% 2,915,944 0.96% $34,787,212
BRAIDWELL LP 2.9% 2,526,009 1.3% $30,135,287
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,859,023 0% $22,183,186
Aisling Capital Management LP 1.8% 1,555,664 6.2% $18,559,072
DIMENSIONAL FUND ADVISORS LP 1.6% 1,381,344 0% $16,478,063
MPM BIOIMPACT LLC 1.3% 1,125,216 1% $13,423,827
Opaleye Management Inc. 1.2% 1,035,000 1.4% $12,347,550
Frazier Life Sciences Management, L.P. 1.2% 1,000,000 0.3% $11,930,000
GOLDMAN SACHS GROUP INC 1% 871,795 0% $10,400,518
Point72 Asset Management, L.P. 0.9% 770,673 0.01% $9,194,129
Nextech Invest Ltd. 0.89% 761,153 0.41% $9,080,555
VANGUARD PORTFOLIO MANAGEMENT LLC 0.88% 755,736 0% $9,015,930
Woodline Partners LP 0.87% 750,884 0.03% $8,958,046
Nantahala Capital Management, LLC 0.84% 721,064 0.48% $8,602,294
TWO SIGMA INVESTMENTS, LP 0.78% 667,435 0.01% $7,962,500
KENNEDY CAPITAL MANAGEMENT LLC 0.69% 595,463 0.13% $7,103,874

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
22
Headline period
Q3 2026
Rows shown
1-22 of 22
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 70,778,806 $844,305,006 -$34,381,178 $11.93 135
2026 Q2 92,668,800 $2,241,872,344 +$143,074,744 $24.20 192
2026 Q1 86,952,318 $1,430,282,358 +$355,307,204 $16.45 189
2025 Q4 64,480,520 $1,011,031,344 +$79,666,435 $15.68 161
2025 Q3 60,027,627 $444,802,878 -$4,386,129 $7.41 126
2025 Q2 62,196,889 $280,514,086 +$11,963,150 $4.51 115
2025 Q1 59,523,717 $276,191,314 -$11,913,266 $4.64 105
2024 Q4 60,988,332 $423,262,031 +$79,110,231 $6.94 104
2024 Q3 49,754,753 $263,674,421 +$18,158,687 $5.30 80
2024 Q2 45,836,316 $171,427,053 +$21,976,071 $3.74 73
2024 Q1 39,892,581 $281,249,822 -$731,896 $7.05 67
2023 Q4 40,102,427 $226,575,690 -$10,023,054 $5.65 71
2023 Q3 42,042,126 $201,382,486 +$10,940,133 $4.79 70
2023 Q2 39,734,743 $272,184,520 -$3,199,539 $6.85 67
2023 Q1 39,769,032 $309,801,540 -$11,077,618 $7.79 69
2022 Q4 41,325,746 $314,458,629 +$7,213,706 $7.61 66
2022 Q3 40,353,101 $329,604,037 -$3,246,200 $8.17 70
2022 Q2 38,778,221 $374,994,819 -$11,927,308 $9.67 56
2022 Q1 39,943,480 $559,876,587 +$42,034,475 $14.02 52
2021 Q4 36,340,047 $741,974,000 +$28,074,571 $20.42 53
2021 Q3 34,892,057 $759,420,127 +$60,728,601 $22.28 54
2021 Q2 32,095,195 $705,074,000 +$705,074,000 $22.70 48
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .